[A <u>new study</u> suggests] that improving vitamin D status in the general population, and in particular in patients hospitalized with COVID-19, could help to reduce the severity of COVID-19 disease and associated deaths. The study, reported in PLOS ONE, found that hospitalized COVID-19 patients who had sufficient vitamin D—i.e., they had blood levels of 25-hydroxyvitamin D of at least 30 ng/mL—had a significantly lower risk of adverse clinical outcomes, including becoming unconscious, hypoxia, and death, than patients who were vitamin D deficient.

In addition, patients who were vitamin D sufficient had lower blood levels of the inflammatory marker Creactive protein, and higher blood lymphocyte levels. "This study provides direct evidence that vitamin D sufficiency can reduce the complications, including the cytokine storm (release of too many proteins into the blood too quickly) and ultimately death from COVID-19," commented Michael F. Holick, PhD, MD, professor of medicine, physiology and biophysics and molecular medicine at Boston University School of Medicine.

Follow the latest news and policy debates on sustainable agriculture, biomedicine, and other 'disruptive' innovations. Subscribe to our newsletter. SIGN UP

Vitamin D interaction with its receptor in immune cells modulates the innate and acquired immune systems in response to invasion of bacterial and viral pathogens. Vitamin D also modulates the renin-angiotensin pathway and downregulates ACE2. "Therefore, vitamin D might help in treatment of COVID-19 by preventing the cytokine storm and subsequent ARDS [acute respiratory distress syndrome] which is commonly the cause of mortality," the authors commented.

Read the original post